Navidea Biopharmaceuticals, Inc (NAVB)
-NYSE MKT 2.69 
0.14(5.49%) Jun 17, 4:04PM EDT|After Hours
:
2.69 0.00 (0.00%) Jun 17, 4:30PM EDT
| Prev Close: | 2.55 |
|---|
| Open: | 2.69 |
|---|
| Bid: | 2.45 x 500 |
|---|
| Ask: | 2.70 x 200 |
|---|
| 1y Target Est: | 5.19 |
|---|
| Beta: | 1.01 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 2.56 - 2.70 |
|---|
| 52wk Range: | 2.14 - 4.77 |
|---|
| Volume: | 631,011 |
|---|
| Avg Vol (3m): | 980,805 |
|---|
| Market Cap: | 314.07M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.28 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Navidea's Lymphoseek shows positive meta-analysis resultsat theflyonthewall.com(Wed, Jun 12)
- Navidea Biopharmaceuticals Announces Presentation of Meta-Analysis Results of Lymphoseek® and ACOSOG Radiolabeled Colloid in Head and Neck CancerBusiness Wire(Wed, Jun 12)
- Navidea Biopharmaceuticals Announces Results from Lymphoseek® Study on Accuracy of Lymph Node Detection from Injection Time to SurgeryBusiness Wire(Tue, Jun 11)
- Navidea Biopharmaceuticals Announces Presentation of Results from Two Lymphoseek® and Radiolabeled Colloid Studies in Lymphatic Mapping for Breast Cancer at SNMMIBusiness Wire(Mon, Jun 10)
- Navidea Announces Data Presentations at 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)Business Wire(Tue, Jun 4)
- SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Navidea Biopharmaceuticals, Inc.PR Newswire(Mon, Jun 3)
- Navidea Biopharmaceuticals Announces Highlights of Lymphoseek® Data Presented at Joint International Oncology Congress (JIOC)Business Wire(Wed, May 29)
- Navidea Biopharmaceuticals to Present at the Jefferies 2013 Global Healthcare ConferenceBusiness Wire(Wed, May 29)
- Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Joint International Oncology Congress (JIOC)Business Wire(Wed, May 22)
- NAVIDEA BIOPHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, FinancEDGAR Online(Thu, May 16)
- Angelina Jolie's Selfless Act Heightens Breast Cancer Awarenessat Motley Fool(Wed, May 15)
- Nordion signs contract manufacturing agreement with Navideatheflyonthewall.com(Wed, May 15)
- Navidea Biopharmaceuticals Signs Manufacturing and Supply Agreement with NordionBusiness Wire(Wed, May 15)
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 4,456.42 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.22 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.06 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision diagnostics and radiopharmaceutical agents.
View More